Lode Schuerman

ORCID, self-asserted

ORCID 0000-0003-0697-6242

Publications

Citations

182

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

9 works in the graph, newest first.

Effectiveness of the RTS,S/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi
2025The Lancet Global HealthJournalOpen access9 citations10.1016/s2214-109x(25)00415-2
Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study
2025The Lancet Global HealthJournalOpen access8 citations10.1016/s2214-109x(25)00096-8
Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial
2025The Lancet Global HealthJournalOpen access3 citations10.1016/s2214-109x(25)00272-4
Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022
2025The Lancet Global HealthJournalOpen access4 citations10.1016/s2214-109x(25)00022-1
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
2024The Journal of Infectious DiseasesJournalOpen access4 citations10.1093/infdis/jiae075
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
2023The Lancet Respiratory MedicineJournalOpen access25 citations10.1016/s2213-2600(23)00263-1
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
2023EClinicalMedicineJournalOpen access11 citations10.1016/j.eclinm.2023.102168
Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
2022The Lancet Infectious DiseasesJournalOpen access75 citations10.1016/s1473-3099(22)00273-0
Assessing the safety, impact and effectiveness of RTS,S/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up
2022Malaria JournalJournalOpen access43 citations10.1186/s12936-022-04144-3